NW
ALNY icon

NewEdge Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History

NewEdge Wealth’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.74M Sell
9,094
-107
-1% -$32.3K 0.03% 379
2026
Q1 		$3.04M Buy
9,201
+1,671
+22% +$569K 0.04% 328
2025
Q4 		$2.99M Sell
7,530
-463
-6% -$205K 0.03% 349
2025
Q3 		$3.47M Buy
7,993
+7,091
+786% +$2.89M 0.05% 278
2025
Q2 		$392K Buy
+902
New +$250K 0.01% 763

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NewEdge Wealth's ALNY Position: Q2 2026 in Review

NewEdge Wealth reduced its Alnylam Pharmaceuticals (ALNY) stake by 1.2% in Q2 2026, selling an estimated $32.3K and leaving 9,094 shares worth $2.74M. The position accounts for 0.03% of the portfolio, ranked #379.

NewEdge Wealth first reported a position in ALNY in Q2 2025 and has held it in 5 quarters since. The position peaked at $3.47M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • NewEdge Wealth held 9,094 shares of Alnylam Pharmaceuticals worth $2.74M as of Q2 2026.
  • NewEdge Wealth sold 107 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $32.3K.
  • Alnylam Pharmaceuticals made up 0.03% of NewEdge Wealth's portfolio in Q2 2026, its #379 holding.
  • NewEdge Wealth first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • NewEdge Wealth's Alnylam Pharmaceuticals position peaked at $3.47M in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on NewEdge Wealth's 13F filing for Q2 2026, filed 10 Aug 2026.